STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Synta Pharmaceuticals Corp.
ClinicalTrials.gov Identifier:
NCT00088101
First received: July 20, 2004
Last updated: December 3, 2008
Last verified: December 2008
  Purpose

The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.


Condition Intervention Phase
Hematological Malignancies
Leukemia
Lymphoma
Metastatic or Unresectable Solid Tumors
Drug: STA-5312
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors

Resource links provided by NLM:


Further study details as provided by Synta Pharmaceuticals Corp.:

Estimated Enrollment: 42
Study Start Date: February 2004
Estimated Study Completion Date: December 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients 18 years or older with one of the following malignancies:
  • Histologically or cytologically confirmed hematological malignancy (other than Acute Myeloid Leukemia and Myelodysplastic Syndrome) and if treatment is medically indicated, or,
  • Histologically-confirmed non-hematological malignancy that is metastatic or unresectable and for which no standard therapy is available.
  • Patients with CLL, PLL, CML, CTCL, ATL, and Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g. chlorambucil and cyclophosphamide), anthracycline combinations [e.g. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)], and/or purine analogues (e.g. fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens
  • Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria [low-risk, intermediate-risk and high risk]. All patients in the high-risk group (Stage III and IV) are eligible. Intermediate risk patients (Stage I and II) with one or more criteria of active disease (such as progressive lymphocytosis, lymphadenopathy, and splenomegaly, weight loss > 10% within 6 months, extreme fatigue, fever and/or night sweats without evidence of infection, etc.) are also eligible
  • ECOG Performance Status of 0-2
  • Life expectancy of greater than 12 weeks.
  • Patients must have acceptable organ and marrow function at screening and pre-dose visits as defined below unless approved medically by the clinical investigator.
  • Absolute neutrophils count greater than 1,000 cells/ul for patients with hematologic malignancies and ≥1,500 cells/ul for patients with solid tumors
  • Platelets greater than 100,000/ul
  • Hgb greater than 8.5 g/dL
  • Total bilirubin must be <1.5 mg/dL or < 2X upper limit of normal
  • AST (SGOT) < 2.5 times the upper limit of normal
  • ALT (SGPT) < 2.5 times the upper limit of normal
  • Adequate renal function (serum creatinine < 2.0 mg/dL or a calculated creatinine clearance greater than 50 mL/min)
  • Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator.
  • NCI grade 0-1 left ventricular ejection fraction within 30 days of dosing.
  • The effects of STA-5312 on the developing human fetus are unknown. Therefore, women of childbearing potential (defined as women under 50 years of age or history of amenorrhea for < 12 months prior to study entry) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Patients who have had chemotherapy, radiotherapy (except palliative radiation delivered to < 20% of bone marrow), immunotherapy, or corticosteroids ( > 10 mg/day of prednisone or equivalent) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • The use of nitrosoureas or mitomycin C within 6 weeks prior to study entry.
  • Patients with prior peripheral blood stem cell rescue or bone marrow transplantation.
  • History of primary brain tumors or active brain metastases. (Patients with previously treated brain metastases who are not receiving corticosteroids or anticonvulsants may be considered for enrollment)
  • History of stroke or other significant neurologic limitations within 6 months prior to study enrollment
  • Use of any investigational agents within 4 weeks of study enrollment.
  • History of severe allergic reactions to excipients (e.g. Tween 80) or had hypersensitivity reactions to other chemotherapeutic agents similar in structure to STA-5312.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
  • History of active CNS-lymphoma, AIDS-related lymphoma, or any uncontrolled severe medical illness or infection.
  • Grade 2 or higher sensory or motor neuropathy at screening.
  • Major surgery (excluding that for diagnosis) within 4 weeks of enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00088101

Locations
United States, California
Wilshire Oncology Medical Group
Pamona, California, United States, 91767
United States, Florida
Baptist Cancer Institute
Jacksonville, Florida, United States, 32207
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Massachusetts
Tufts New England Medical Center
Boston, Massachusetts, United States, 02111
United States, New Jersey
Newark Beth Israel Medical Center
Newark, New Jersey, United States
United States, North Carolina
Carolinas HealthCare System
Charlotte, North Carolina, United States, 28203
United States, Tennessee
The West Clinic
Memphis, Tennessee, United States, 38120
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00088101     History of Changes
Other Study ID Numbers: 5312-01
Study First Received: July 20, 2004
Last Updated: December 3, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Synta Pharmaceuticals Corp.:
Hematological Malignancies
Leukemia
Lymphoma
Metastatic
Unresectable solid tumors

Additional relevant MeSH terms:
Neoplasms
Leukemia
Lymphoma
Hematologic Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Hematologic Diseases

ClinicalTrials.gov processed this record on August 21, 2014